Natural Products as Pharmaceuticals and Sources for Lead Structures

The Practice of Medicinal Chemistry: Second Edition

Volumn , Issue , 2003, Pages 91-109

  Newman, David J ^a   Cragg, Gordon M ^a   Kingston, David G I ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENES;

BIOACTIVE COMPOUNDS; DERIVED MATERIALS; GENETIC INFORMATION; GENETIC TECHNIQUES; MARINE INVERTEBRATES; NATURAL PRODUCTS; PARASITIC INFECTIONS; SECONDARY METABOLITES;

METABOLITES;

EID: 53349180372     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012744481-9/50010-6     Document Type: Chapter

References (86)

1. Anon A pictorial history of herbs in medicine and pharmacy. Herbalgram 1998, 33-47.
2. Grabley S., Thiericke R. Bioactive agents from natural sources: trends in discovery and application. Adv. Biochem. Eng./Biotech. 1999, 64:104-154.
3. Haslam E. Secondary metabolism - fact and fiction. Nat. Prod. Rep. 1986, 3:217-249.
4. Williams D.H., Stone M.J., Hauck P.R., Rahman S.K. Why are secondary metabolites (natural products) biosynthesized?. J. Nat. Prod. 1989, 52:1189-1208.
5. Harborne J.B. Role of secondary metabolites in chemical defence mechanisms in plants. Bioactive Compounds from Plants 1990, 126-139. Wiley, New York. D.J. Chadwick, J. Marsh (Eds.).
6. Olivera B.M. Conus venom peptides, receptor and ion channel targets, and drug design: 50 million years of neuropharmacology. Mol. Biol. Cell 1997, 8:2101-2109.
7. Cragg G.M., Newman D.J., Snader K.M. Natural products in drug discovery and development. J. Nat. Prod. 1997, 60:52-60.
8. Cragg G.M., Newman D.J. Antineoplastic agents from natural sources: achievements and future directions. Exp. Opin. Invest. Drugs 2000, 9:2783-2797.
9. Newman D.J., Cragg G.M., Snader K.M. The influence of natural products on drug discovery. Nat. Prod. Rep. 2000, 17:215-234.
10. Newman D.J., Laird S.A. The influence of natural products on 1997 pharmaceutical sales figures. The Commercial Use of Biodiversity 1999, 333-335. Earthscan Publications, Chichester. K. ten Kate, S.A. Laird (Eds.).
11. Vagelos P.R. Are prescription drug prices high?. Science 1991, 252:1080-1084.
12. Schreiber S.L., Tan D.S., Foley M.A., Shair M.D. Stereoselective synthesis of over two million compounds having structural features both reminiscent of natural products and compatible with miniaturized cell-based assays. J. Am. Chem. Soc. 1998, 120:8565-8566.
13. Downes D., Laird S.A., Klein C., Carney B.K. Biodiversity prospecting contract. Biodiversity Prospecting: Using Genetic Resources for Sustainable Development 1993, 255-287. World Resources Institute, London. W.V. Reid, S.A. Laird, C.A. Meyer, R. Gamez, A. Sittenfeld, D.H. Janzen, M.A. Gollin, C. Juma (Eds.).
14. Baker J.T., Borris R.P., Carte B., Cordell G.A., Soejarto D.D., Cragg G.M., Gupta M.P., Iwu M.M., Madulid D.R., Tyler V.E. Natural product drug discovery and development: new perspectives on international collaboration. J. Nat. Prod. 1995, 58:1325-1357.
15. ten Kate K., Wells A. Benefit-Sharing Case Study. The Access and Benefit-Sharing Policies of the United States National Cancer Institute: A Comparative Account of the Discovery and Development of the Drugs Calanolide and Topotecan. Submission to the Executive Secretary of the Convention on Biological Diversity 1998, The Royal Botanic Gardens, Washington, DC.
16. Rosenthal J.P. Drug discovery, economic development and conservation: the International Cooperative Diodiversity Groups. Pharm. Biol. 1999, 37:5.
17. Farnsworth N.R. The role of ethnopharmacology in drug development. Bioactive Compounds from Plants 1990, 2-21. Wiley, Kew, UK. D.J. Chadwick, J. Marsh (Eds.).
18. Cox P.A. Ethnopharmacology and the search for new drugs. Bioactive Compounds from Plants 1990, 40-55. Wiley, Chichester. D.J. Chadwick, J. Marsh (Eds.).
19. Balick M.J. Ethnobotany and the identification of therapeutic agents from the rainforest. Bioactive Compounds from Plants 1990, 22-39. Wiley, Chichester. D.J. Chadwick, J. Marsh (Eds.).
20. Plotkin M.J. Conservation, ethnobotany and the search for new jungle medicines: pharmacognosy comes of age ... Again. Pharmacotherapy 1988, 8:257-262.
21. Cragg G.M., Boyd M.R., Cardellina J.H., Newman D.J., Snader K.M., McCloud T.G. Ethnobotany and drug discovery: the experience of the US National Cancer Institute. Ethnobotany and the Search for New Drugs, Ciba Foundation Symposium 1994, vol. 185:178-196. Wiley, Chichester. D.J. Chadwick, J. Marsh (Eds.).
22. Kingston D.G.I., Abdel-Kader M., Zhou B.-N., Yang S.-W., Berger J.M., van der Werff H., Miller J.S., Evans R., Mittermeier R., Famolare L., Guerin-McManus M., Malone S., Nelson R., Moniz E., Wisse J.H., Vyas D.M., Wright J.J.K., Aboikonie S. The Suriname International Cooperative Biodiversity Group Program: Lessons from the first five years. Pharm. Biol. 1999, 37:22-34. (suppl.).
23. Coombes J.D. New Drugs from Natural Sources 1992, IBC Technical Services, Chichester.
24. Boyd M.R., Paull K.D. Some practical considerations and applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Dev. Res. 1995, 34:91-109.
25. Johnson R.K., Bartus H.F., Hofmann G.A., Bartus J.O., Mong S.-M., Faucette L.F., McCabe F.L., Chan J.A., Mirabelli C.K. Discovery of new DNA-reactive drugs. Organizing Committee of the 14th International Congress of Chemotherapy 1986, 15-26. L.J. Hanka, T. Kondo, R.J. White (Eds.).
26. Meyer B.N., Ferrigni N.R., Putnam J.E., Jacobsen L.B., Nichols D.E., McLaughlin J.L. Brine shrimp: a convenient general bioassay for active plant constituents. Planta Med. 1982, 45:31-34.
27. McLaughlin J.L. Crown gall tumours on potato discs and brine shrimp lethality: two simple bioassays for higher plant screening and fractionation. Methods in Plant Biochemistry: Assays for Bioactivity 1991, vol. 6:1-32. Academic Press, London, UK. K. Hostettmann (Ed.).
28. Shimizu Y. Bioactive marine natural products with emphasis on handling of water-soluble compounds. J. Nat. Prod. 1985, 48:223-235.
29. Marston A., Hostettmann K. Modern separation methods. Nat. Prod. Rep. 1991, 8:391-413.
30. Hostettmann K., Wolfender J.-L., Rodriguez S. Rapid detection and subsequent isolation of bioactive constituents of crude plant extracts. Planta Med. 1997, 63:2-10.
31. Cordell G.A. Changing strategies in natural products chemistry. Phytochemistry 1995, 40:1612-1685.
32. Cragg G.M., Schepartz S.A., Suffness M., Grever M.R. The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J. Nat. Prod. 1993, 56:1657-1668.
33. Fujita Y. Industrial production of shikonin and berberine. Applications of Plant Cell and Tissue Culture 1988, 157-174. Wiley, San Diego. G. Bock, J. Marsh (Eds.).
34. Fowler M.W., Cresswell R.C., Stafford A.M. An economic and technical assessment of the use of plant cell cultures for natural product synthesis on an industrial scale. Bioactive Compounds from Plants 1990, 228-238. Wiley, Chichester. D.J. Chadwick, J. Marsh (Eds.).
35. Ferreira S.H. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br. J. Pharmacol. 1965, 24:163-169.
36. Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active hypertensive agents. Science 1977, 196:441-444.
37. Cushman D.W., Cheung H.S., Sabo E.F., Ondetti M.A. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977, 16:5484-5491.
38. Endo A., Kuroda M., Tsujita Y., Terahara A., Tamura C. Physiologically Active Compounds 1975, German Patent No. 2524355.
39. Endo A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. J. Med. Chem. 1985, 28:401-405.
40. Brown A.G., Smale T.C., King T.J., Hasenkamp R., Thompson R.H. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J. Chem. Soc. Perkin Trans. 1976, 1:1165-1170.
41. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J. Antibiot. 1979, 32:852-854.
42. Endo A. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Antibiot. 1980, 33:334-336.
43. Alberts A.W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monaghan R., Currie S., Stapley E., Albers-Shonberg G., Hensens O., Hirshfield J., Hoogsteen K., Liesch J., Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethyl-glutaryl-coenzyme A reductase and a cholesterol lowering agent. Proc. Natl Acad. Sci. USA 1980, 77:3957-3961.
44. Monaghan R.L., Alberts A.W., Hoffman C.G., Albers-Schonberg G. Hypocholesteremic fermentation products and process of preparation 1980, USA Patent No. 4231938.
45. Alberts A.W., MacDonald J.S., Till A.E., Tobert J.A. Lovastatin. Cardiol. Drug. Dev. 1989, 7:89-109.
46. Vagelos P.R. Are prescription drug prices high?. Science 1991, 252:1080-1084.
47. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000, 6:1399-1402.
48. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
49. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57:1439-1443.
50. Meyer C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. J. Am. Med. Assoc. 2000, 283:3255-3257.
51. Borel, J.F. (ed.). In Progress in Allergy, vol. 38. Cyclosporin, pp. 102-465. Karger, Basel.
52. Cropp T.A., Wilson D.J., Reynolds K.A. Identification of a cyclohexylcarbonyl CoA biosynthetic gene cluster and application in the production of doramectin. Nat. Biotechnol. 2000, 18:980-983.
53. Suffness M., Wall M.E. Discovery and development of taxol. Taxol: Science and Applications 1995, 3-25. CRC Press, Chichester. M. Suffness (Ed.).
54. Cortes J.E., Pazdur R. Docetaxel. J. Clin. Oncol. 1995, 13:2643-2655.
55. Kingston D.G.I., Chaudhary A.G., Chordia M.D., Gharpure M., Gunatilaka A.A.L., Higgs P.I., Rimoldi J.M., Samala L., Jaktap P.G., Giannakakou P., Jiang Y.Q., Lin C.M., Hamel E., Long B.H., Fairchild C.R., Johnston K.A. Synthesis and biological evaluation of 2-acyl analogs of paclitaxel (Taxol). J. Med. Chem. 1998, 41:3715-3726.
56. von Angerer E. Tubulin as a target for anticancer drugs. Curr. Opin. Drug Disc. Dev. 2000, 3:575-584.
57. Hartwell J.L., Schrecker A.W. Chemistry of podophyllum. Fortschritte Chemie der Organische Naturstoffe 1958, vol. 15:83-166. Springer-Verlag, Boca Raton, FL. L. Zechmeister (Ed.).
58. Chen G.L., Yang L., Rowe T.C., Halligan B.D., Tewey K., Liu L. Nonintercalative antitumor drugs interfere with the breakage-reunion of mammalian DNA topoisomerase II. J. Biol. Chem. 1984, 259:13560-13566.
59. Noble R.L., Beer C.T., Cutts J.H. Role of chance observations in chemotherapy: Vinca rosea. Ann. NY Acad. Sci. 1958, 76:882-894.
60. Johnson I.S., Wright H.F., Suoboda G.H., Lantis J. Antitumor principles derived from Vinca rosea Linn. I. Vincaleukoblastine and leurosine. Cancer Res. 1960, 40:1016-1022.
61. Pezzuto J.M. Plant-derived anticancer agents. Biochem. Pharmacol. 1997, 53:121-133.
62. Potmeisel M., Pinedo H. Camptothecins: New Anticancer Agents 1995, CRC Press, Vienna.
63. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation and characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl Acad. Sci. USA 1987, 84:5449-5453.
64. Brotzu G. Research as a new antibiotic. Lav. Ist. Igiene Cagliari 1948.
65. Mateles R.I. Penicillin: A Paradigm for Biotechnology 1998, Candida Corporation, Boca Raton.
66. Imada A., Kitano K., Kintaka K., Muroi M., Asai M. Sulfazecin and isosulfazecin, novel beta-lactam antibiotics of bacterial origin. Nature 1981, 289:590-591.
67. Sykes R.B., Cimarusti C.M., Bonner D.P., Bush K., Floyd D.M., Georgopapadakou N.H., Koster W.H., Liu W.C., Parker W.L., Principe P.A., Rathnum M.L., Slusarchyk W.A., Trejo W.H., Wells J.S. Monocyclic beta-lactam antibiotics produced by bacteria. Nature 1981, 291:489-491.
68. Ryan B., Ho H.-T., Wu P., Frosco M.-B., Dougherty T., Barrett J.F. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Exp. Opin. Invest. Drugs 2000, 9:2945-2972.
69. Terry C.E., Pellens M. The Opium Problem 1928, Bureau of Social Hygiene, Chicago.
70. Musto D.F. The American Disease 1973, Yale University Press, New York.
71. Gray N.S., Wodicka L., Thunnissen A.-M.W.H., Norman T.C., Kwon S., Espinosa F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., Kim S.-H., Lockhart D.J., Schultz P.G. Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors. Science 1998, 281:533-538.
72. Gray N., Detivaud L., Doerig C., Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6:859-875.
73. Chang Y.T., Gray N.S., Rosania G.R., Sutherlin D.P., Kwon S., Norman T.C., Sarohia R., Leost M., Meijer L., Schultz P.G. Synthesis and application of functionally diverse 2,6, 9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6:361-375.
74. Nicolaou K.C., Winssinger N., Vourloumis D., Ohshima T., Kim S., Pfefferkorn J., Xu J.-Y., Li T. Solid and solution phase synthesis and biological evaluation of combinatorial sarcodictyin libraries. J. Am. Chem. Soc. 1998, 120:10814-10826.
75. Hamel E., Sackett D.L., Vourloumis D., Nicolaou K.C. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 1999, 38:5490-5498.
76. Nicolaou K.C., Roschangar F., Vourloumis D. Chemical biology of epothilones. Angew. Chem. Int. Ed. Engl. 1998, 37:2014-2045.
77. Zhao L., Ahlert J., Xue Y., Thorson J.S., Sherman D.H., Liu H.-W. Engineering a methymycin/pikromycin-calicheamicin hybrid: construction of two new macrolides carrying a designed sugar moiety. J. Am. Chem. Soc. 1999, 121:9881-9882.
78. Hutchinson C.R. Microbial polyketide synthases: more and more prolific. Proc. Natl Acad. Sci. USA 1999, 96:3336-3338.
79. Wender P.A., Hinkle K.W., Koehler M.F., Lippa B. The rational design of potential therapeutic agents: synthesis of bryostatin analogs. Med. Res. Rev. 1999, 19:388-407.
80. Wender P.A., De Brabander J., Harran P.G., Jimenez J.-M., Koehler M.F.T., Lippa B., Park C.-M., Shiozaki M. Synthesis of the first members of a new class of biologically active bryostatin analogs. J. Am. Chem. Soc. 1998, 120:4534-4535.
81. Wender P.A., De Brabander J., Harran P.G., Jimenez J.-M., Koehler M.F.T., Lippa B., Park C.-M., Siedenbiedel C., Pettit G.R. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. Proc. Natl Acad. Sci. USA 1998, 95:6624-6629.
82. Wender P.A., De Brabander J., Harran P.G., Hinkle K.W., Lippa B., Pettit G.R. Synthesis and biological evaluation of fully synthetic bryostatin analogs. Tetrahedron Lett. 1998, 39:8625-8628.
83. Wender P.A., Lippa B., Park C.-M., Irie K., Nakahara A., Ohigashi H. Selective binding of bryostatin analogs to the cysteine rich domains of protein kinase C isozymes. Bioorg. Med. Chem. Lett. 1999, 9:1687-1690.
84. Haygood M.G., Davidson S.K. Small-subunit rRNA genes and in situ hybridization with oligonucleotides specific for the bacterial symbionts in the larvae of the bryozoan Bugula neritina and proposal of "Candidatus endobugula sertula". Appl. Environ. Microbiol. 1997, 63:4612-4616.
85. Haygood M.G., Schmidt E.W., Davidson S.K., Faulkner D.J. Microbial symbionts of marine invertebrates: opportunities for microbial biotechnology. J. Mol. Microbiol. Biotechnol. 1999, 1:33-43.
86. Mutter R., Wills M. Chemistry and clinical biology of the bryostatins. Bioorg. Med. Chem. 2000, 8:1841-1860.